NOVN Novan Inc.

0.64
-0.03  -5%
Previous Close 0.68
Open 0.65
Price To Book -0.62
Market Cap 17,204,689
Shares 26,715,356
Volume 565,384
Short Ratio
Av. Daily Volume 505,231
Stock charts supplied by TradingView

NewsSee all news

  1. Novan Reports Top-Line Efficacy Results from Phase 3 Trials of SB206 for Molluscum Contagiosum

    Company to hold conference call Friday, January 3, 2020 at 8:30 am Eastern TimeFocus of call: top-line efficacy data and sensitivity analyses MORRISVILLE, N.C., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. ("the

  2. Novan Announces Planned Chief Executive Officer Transition

    Paula Brown Stafford appointed as CEO effective February 2, 2020G. Kelly Martin's term as CEO will end on February 1, 2020, per his employment contractMr. Martin will step down from the Novan Board of Directors effective

  3. François Nader, M.D., Joins Moderna's Board of Directors

    Former CEO of NPS Pharmaceuticals brings broad expertise to support Moderna's progress towards late-stage development and commercialization

  4. Novan's Phase 2 SB206 Molluscum Study Published in Journal of the American Academy of Dermatology

    MORRISVILLE, N.C., Oct. 08, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that the Company's Phase 2 molluscum study, designed to evaluate topical nitric

  5. Novan Awarded Approximately $1.1 Million Grant by Department of Defense

    Funds to progress women's health product candidate, WH504Additive to recently announced NIH grant for WH602Women's health initiative to focus on potential HPV related onco-virus therapeutics MORRISVILLE, N.C., Sept.

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 data released November 29, 2016. Primary endpoint met.
SB206
Human papillomavirus (HPV)
Phase 2 data released April 12, 2017. Primary endpoint met.
SB208
Fungal infections
Phase 3 top-line data released January 27, 2017. Met one of three co-primary endpoints in NI-AC301 trial. Met all endpoints in NI-AC302 trial. Additional Phase 3 trial required.
SB204
Acne vulgaris
Phase 3 data did not meet primary endpoint - January 2, 2020.
SB206
Molluscum contagiosum skin infection
Phase 2 trial to be initiated 4Q 2019.
SB414
Atopic Dermatitis

Latest News

  1. Novan Reports Top-Line Efficacy Results from Phase 3 Trials of SB206 for Molluscum Contagiosum

    Company to hold conference call Friday, January 3, 2020 at 8:30 am Eastern TimeFocus of call: top-line efficacy data and sensitivity analyses MORRISVILLE, N.C., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. ("the

  2. Novan Announces Planned Chief Executive Officer Transition

    Paula Brown Stafford appointed as CEO effective February 2, 2020G. Kelly Martin's term as CEO will end on February 1, 2020, per his employment contractMr. Martin will step down from the Novan Board of Directors effective

  3. François Nader, M.D., Joins Moderna's Board of Directors

    Former CEO of NPS Pharmaceuticals brings broad expertise to support Moderna's progress towards late-stage development and commercialization

  4. Novan's Phase 2 SB206 Molluscum Study Published in Journal of the American Academy of Dermatology

    MORRISVILLE, N.C., Oct. 08, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that the Company's Phase 2 molluscum study, designed to evaluate topical nitric

  5. Novan Awarded Approximately $1.1 Million Grant by Department of Defense

    Funds to progress women's health product candidate, WH504Additive to recently announced NIH grant for WH602Women's health initiative to focus on potential HPV related onco-virus therapeutics MORRISVILLE, N.C., Sept.

  6. Novan Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    MORRISVILLE, N.C., Sept. 11, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that the Compensation Committee of Novan's Board of Directors granted stock

  7. Novan and Aspire Capital Enter into a Common Stock Purchase Agreement for up to $25 Million

    MORRISVILLE, N.C., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that the Company has entered into a Common Stock Purchase Agreement (the

  8. Novan Hires Michelle Patterson as Vice President of Project Management

    Underscores Company's preparation for potential NDA submission for SB206 in molluscumRole to lead cross-functional coordination of key activities and timelines for the programSB206 top line results are expected no later

  9. Novan to Participate in H.C. Wainwright 21st Annual Global Investment Conference

    MORRISVILLE, N.C., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that it will participate in the H.C. Wainwright 21st Annual Global Investment